In a Nature Reviews Cancer Viewpoint article published online this week, four leading experts – Chi V. Dang, E. Premkumar Reddy, Kevan M. Shokat, and VHIO´s Laura Soucek, discuss progress marked thus far towards drugging desirable targets in cancer, including the RAS and MYC oncogenes, and underline the remaining challenges and future opportunities in pharmacologically targeting these notoriously difficult to drug proteins.
Co-author Laura Soucek, Principal Investigator of VHIO´s Mouse Models of Cancer Therapies Group, is particularly optimistic in her outlook, stating the case for supporting potential breakthrough science proposed and led by junior researchers. She should know – she´s one of them. It is thanks to her determined spirit combined with her belief in clinically targeting MYC that she has driven over a decade of research that has successfully shown its inhibition as an effective and safe anti-cancer strategy across several tumor types. Closing the article, Laura boldly ends on a promise, ´Mark my words: the undruggable is about to be drugged´.
It seems then, that as far as MYC is concerned, it´s no longer a question of if but when we will be ushering a viable inhibitor into the clinic.
To access the article please click on the following SharedIt link: http://rdcu.be/tEEC